Article successfully added.

CyFlow™ CD105 FITC

CyFlow™ CD105 FITC
Alternative Name: Endoglin
Antibody: Yes
Antigen: CD105
Application: Flow cytometry
Clonality: monoclonal
Clone: MEM-229
Emission Maximum: 518 nm
Excitation Maximum: 490 to 495 nm
Field of Interest: Immunophenotyping
Format/Fluorochrome: FITC
Isotype: IgG2a
Laser: Blue
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human, Pig
Product number: CZ889831

For Research Use Only

$276.71 CAD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
Quantity 100 tests Volume 2.0 mL Immunogen Recombinant Vaccinia virus containing the... more
Close menu
CyFlow™ CD105 FITC
Quantity100 tests
Volume2.0 mL
ImmunogenRecombinant Vaccinia virus containing the human CD105 cDNA
Background InformationCD105 (Endoglin) is a homodimeric transmembrane glycoprotein serving in presence of TGFβR-2 as a receptor for TGFβ-1 and TGFβ-3. CD105 is highly expressed on endothelial cells and promotes angiogenesis during wound healing, infarcts and in a wide range of tumours and its gene expression is stimulated by hypoxia. CD105 prevents apoptosis in hypoxic endothelial cells and also antagonizes the inhibitory effects of TGFβ-1 on vascular endothelial cell growth and migration. Normal cellular levels of CD105 are required for formation of new blood vessels.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 20·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, Bernabeu C, Kumar S: CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci. 2003 Jul 1; 116(13):2677‑85. < PMID: 12746487 > | Zhu Y, Sun Y, Xie L, Jin K, Sheibani N, Greenberg DA: Hypoxic induction of endoglin via mitogen‑activated protein kinases in mouse brain microvascular endothelial cells. Stroke. 2003 Oct; 34(10):2483‑8. < PMID: 12947156 > | Guo B, Slevin M, Li C, Parameshwar S, Liu D, Kumar P, Bernabeu C, Kumar S: CD105 inhibits transforming growth factor‑beta‑Smad3 signalling. Anticancer Res. 2004 May-Jun; 24(3a):1337‑45. < PMID: 15274293 > | Warrington K, Hillarby MC, Li C, Letarte M, Kumar S: Functional role of CD105 in TGF‑beta1 signalling in murine and human endothelial cells. Anticancer Res. 2005 May-Jun; 25(3B):1851‑64. < PMID: 16158917 > | Piao M, Tokunaga O: Significant expression of endoglin (CD105), TGFbeta‑1 and TGFbeta R‑2 in the atherosclerotic aorta: an immunohistological study. J Atheroscler Thromb. 2006 Apr; 13(2):82‑9. < PMID: 16733295 > | Plánka L, Necas A, Srnec R, Rauser P, Starý D, Jancár J, Amler E, Filová E, Hlucilová J, Kren L, Gál P: Use of allogenic stem cells for the prevention of bone bridge formation in miniature pigs. Physiol Res. 2009; 58(6):885‑93. < PMID: 19093735 >

TDS & SDS
Close menu

Safety Data Sheet

Technical Data Sheet